This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.
≥18 years old.
Subjects with recurrent or metastatic solid tumors that cannot accept radical locoregional therapy;
Systemic standard treatment failed or cannot tolerate serious toxicity or lack of standard treatment.
Have 1 or more focus can be accessed according to RECIST 1.1
Central nervous system metastasis or meningeal metastasis with clinical symptoms；
With active infection during screening
Have serious or uncontrolled basic diseases;
Have continuous adverse event caused by previous anti-tumor therapy that might affect the evaluation of drug safety；